The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

Poor survival rates of patients with tumors arising from or disseminating into the brain are attributed to an inability to excise all tumor tissue (if operable), a lack of blood-brain barrier (BBB) penetration of chemotherapies/targeted agents, and an intrinsic tumor radio-/chemo-resistance. Ataxia-...

Descripción completa

Detalles Bibliográficos
Autores principales: Durant, Stephen T., Zheng, Li, Wang, Yingchun, Chen, Kan, Zhang, Lingli, Zhang, Tianwei, Yang, Zhenfan, Riches, Lucy, Trinidad, Antonio G., Fok, Jacqueline H. L., Hunt, Tom, Pike, Kurt G., Wilson, Joanne, Smith, Aaron, Colclough, Nicola, Reddy, Venkatesh Pilla, Sykes, Andrew, Janefeldt, Annika, Johnström, Peter, Varnäs, Katarina, Takano, Akihiro, Ling, Stephanie, Orme, Jonathan, Stott, Jonathan, Roberts, Caroline, Barrett, Ian, Jones, Gemma, Roudier, Martine, Pierce, Andrew, Allen, Jasmine, Kahn, Jenna, Sule, Amrita, Karlin, Jeremy, Cronin, Anna, Chapman, Melissa, Valerie, Kristoffer, Illingworth, Ruth, Pass, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010333/
https://www.ncbi.nlm.nih.gov/pubmed/29938225
http://dx.doi.org/10.1126/sciadv.aat1719

Ejemplares similares

Ejemplares similares